Trump Announces Phased Tariffs Up to 200% on Generic Drug Imports

US President Donald Trump has announced a phased tariff plan on imported generic medicines that could significantly affect pharmaceutical exporters, particularly India, one of the world's largest suppliers of generic drugs. Under the new policy, generic medicines imported into the United States will continue to face zero tariffs for the next two years, before rising to 100 per cent in the third year and 200 per cent thereafter. The policy is intended to encourage pharmaceutical companies to shift manufacturing operations to the United States.

In a statement posted on his Truth Social platform, Trump said the new tariff structure will take effect from August 1, 2026, with the higher tariffs coming into force after a two-year transition period. According to the announcement, imported generic medicines will remain duty-free until August 2028, after which a 100 per cent tariff will apply for one year, followed by a 200 per cent tariff. Trump said the phased approach gives companies sufficient time to establish manufacturing facilities in the United States if they wish to avoid the higher duties.

Explaining the rationale behind the policy, Trump said the objective is to reshore pharmaceutical manufacturing and strengthen domestic production capacity. He stated that companies choosing not to invest in manufacturing plants and equipment in the United States during the transition period would face substantial tariff penalties. The President also clarified that the existing policy governing patented, branded and innovative medicines would remain unchanged, with the new measures specifically targeting generic pharmaceutical imports.

Also Read: Trump Imposes 50% Tariffs On Canadian Goods, Citing Unfair Trade

The announcement has drawn attention in India, which is widely regarded as the "pharmacy of the world" due to its large-scale production of affordable generic medicines. Indian pharmaceutical companies account for nearly 40 per cent of the generic medicines supplied by volume in the US market, making the United States their largest export destination. According to the Global Trade Research Initiative (GTRI), India exported pharmaceutical products worth approximately USD 9.7 billion to the US during the 2024–25 financial year, representing 38 per cent of the country's total pharmaceutical exports of USD 25.8 billion.

While the long-term implications for Indian drug manufacturers remain uncertain, the proposed tariffs could increase costs for exporters that continue producing medicines outside the United States. However, the two-year duty-free period provides companies with time to assess investment opportunities and adjust their manufacturing strategies. Industry analysts are expected to closely examine how multinational pharmaceutical firms respond to the policy before the higher tariff rates come into effect.

The announcement also comes against the backdrop of a trade understanding reached between India and the United States earlier this year. That agreement included a provision stating that India would receive negotiated outcomes regarding generic pharmaceuticals and pharmaceutical ingredients. It remains unclear how Trump's latest tariff policy will interact with those commitments, and further discussions between the two governments are likely as the implementation timeline progresses.

Also Read: Delhi Wakes to Rain as IMD Predicts More Showers Today